Physician profile
Christopher G Pearson
NPI 1043312622
$10,877.68
in general payments reported to CMS, 2019-2025
17 companies · $737 in 2025
The $737 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,128 · 2020: $1,573 · 2021: $342 · 2022: $407 · 2023: $562 · 2024: $4,129 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,265 · Travel and Lodging: $1,582 · Consulting Fee: $1,500 · Entertainment: $81.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,264.64 |
| Travel and Lodging | $1,582.12 |
| Consulting Fee | $1,500.00 |
| Entertainment | $81.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $6,270.88 | 2019-2024 | Acuvue |
| Vertical Pharmaceuticals, LLC | $1,500.00 | 2020 | |
| Alcon Vision LLC | $1,358.46 | 2019-2025 | Dailies Total1, Precision7, Clareon |
| Bausch & Lomb Americas INC. | $438.44 | 2022-2025 | Infuse |
| Coopervision INC. | $407.08 | 2022-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Biotissue Holdings INC. | $144.74 | 2023 | |
| Amgen INC. | $122.35 | 2024 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $121.83 | 2025 | Xdemvy |
| Rxsight INC | $110.13 | 2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $105.89 | 2019-2021 | |
| Allergan, INC. | $94.39 | 2022 | |
| Optovue, INC. | $84.73 | 2021 | |
| Optos, INC. | $81.40 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Novartis Pharmaceuticals Corporation | $37.36 | 2020-2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.